While one can come up with numerous reasons for it to take a long time to do analysis. This is not a typical trial in other ways as well. The total number of patients was tiny. Many had completed their engagement years ago such that all the necessary and available data could be gathered long ago. NWBO had literally years to prepare for this and set up the templates, software, data frameworks, etc.
I find it increasingly difficult to rationalize any legitimate reasons for not having some type of meaningful communications with shareholders.
Instead of trying to justify the hype here via your DD, go back over actual FDA approvals over the last few years and see how the time line and announcements really play out?
That would be DD.
Hint, you will not find anything closely resembling this timeline.